Shots:
- Takeda has reported topline P-III (LATITUDE Atlas) trial data assessing zasocitinib (TAK-279; 30mg, PO, QD) vs deucravacitinib (6mg, QD) in 606 adults with mod. to sev. PsO
- Trial showed that zasocitinib was superior to deucravacitinib in the 1EP, with improved PASI 100 response rates at Wk. 16, plus in all key 2EPs, incl. PASI 90 response & sPGA 0
- Takeda will present the data at upcoming medical congresses, and expects to begin global regulatory submissions for PsO, incl. to the FDA, this fiscal year
Ref: Businesswire | Image: Takeda | Press Release
Related News: Denali Regains Full Rights to Frontotemporal Dementia Therapy as Takeda Exits DNL593 Pact
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
